If your period pattern looks like menopause before 45, the question is not only how to stop hot flashes.
The earlier timing changes what needs to be checked. A 2019 systematic review and meta-analysis of 18 studies with 462,393 postmenopausal women found that menopause before 45 was associated with higher fracture risk than menopause after 45, with an odds ratio of 1.36. [8]
That does not mean one age decides your future risk. It means menopause timing can move bone density, fracture prevention, heart-risk review, fertility, contraception, and hormone therapy fit into the same visit.
First, name the timing correctly
The first step is classification, not a supplement, a home hormone panel, or a generic menopause label.
| Pattern | What it usually means | Why it changes the visit |
|---|---|---|
| Age 45 or older with typical cycle changes | Usual-age perimenopause or menopause may fit clinically. | Testing is often less central unless symptoms, bleeding, or history do not fit. |
| Age 40 through 44 with ovarian function ending | The 2024 international guideline calls this early menopause. [2] | Bone, heart, fertility, contraception, cause, and symptom treatment deserve earlier review. |
| Before 40 with disordered cycles and ovarian insufficiency | This fits the premature ovarian insufficiency pathway. [2] | Workup, counseling, bone density, cardiovascular risk, and hormone replacement discussion are more formal. |
| Surgical or cancer-treatment menopause | The cause may be clear, but the risk review still changes. | Oncology history, uterus status, fertility preservation, clot risk, and symptom control can change options. |
| Hormonal contraception masking bleeding | Menstrual pattern and follicle-stimulating hormone can be harder to interpret. | Testing or stopping contraception should be clinician-directed. |
The 2024 international guideline defines premature ovarian insufficiency as loss of ovarian activity before 40, with amenorrhea or irregular cycles plus elevated gonadotropins and low estradiol. It describes ages 40 through 44 as early menopause. [2]
American College of Obstetricians and Gynecologists guidance for suspected primary ovarian insufficiency in younger patients includes pregnancy, thyroid, and prolactin review, basal follicle-stimulating hormone and estradiol, and repeat follicle-stimulating hormone testing if the first value is in the menopausal range. [3]
The 2024 international guideline uses updated diagnostic criteria: disordered cycles for at least 4 months and one follicle-stimulating hormone value above 25 IU/L, with repeat follicle-stimulating hormone or anti-Mullerian hormone used when uncertainty remains. [2]
Those differences should not become do-it-yourself diagnosis. They mean age, cycle pattern, contraception, hysterectomy status, pregnancy possibility, symptoms, and medical history need to be interpreted together.
Why bone and heart risk move earlier
Earlier estrogen loss creates a longer low-estrogen window before the usual age of menopause. That is why this review should not stop after hot flashes and sleep.
Bone risk is the most practical example. The fracture meta-analysis found higher fracture risk with menopause before 45 compared with menopause after 45, but it also found heterogeneity across studies and did not show a distinct effect by fracture site. [8]
For one person, the next question is not "Am I doomed to fracture?" It is "Do I need earlier bone-density testing or a fracture-risk plan because of timing plus my risk factors?"
The 2024 premature ovarian insufficiency guideline recommends bone mineral density testing with dual-energy X-ray absorptiometry at diagnosis of premature ovarian insufficiency where available. If bone density is normal and adequate systemic hormone therapy is started and followed, it says repeating the scan within 5 years has low value. If osteoporosis or low bone density is present, it recommends reassessment every 1 to 3 years based on individual risk factors. [2]
Cardiometabolic risk belongs in the same conversation. A 2023 systematic review and meta-analysis of 20 cohort studies with 921,517 participants found higher long-term cardiometabolic risks in premature or early menopause compared with menopause after 45. Premature menopause had higher relative risks for type 2 diabetes (1.32), hyperlipidemia (1.21), coronary heart disease (1.52), stroke (1.27), and total cardiovascular events (1.36). Early menopause showed smaller significant signals for hyperlipidemia (1.17) and coronary heart disease (1.19), while the type 2 diabetes, stroke, and total cardiovascular event estimates were less certain because their confidence intervals crossed no effect. [5]
A separate cardiovascular meta-analysis included 16 studies, 40,549 women with premature ovarian insufficiency, and 1,016,633 controls. After adjustment for hormone therapy, premature ovarian insufficiency was associated with higher adjusted hazard ratios for composite cardiovascular events and coronary heart disease, but not a clear difference in stroke or cardiovascular death in the pooled analysis. [6]
These are population risk signals, not a prediction for one woman. The useful output is a plan for blood pressure, lipids, glucose, smoking, family history, migraine, clot history, exercise, and follow-up.
Narrow studies should not drive the whole plan
The held evidence on early menopause and fracture risk is useful only if it is kept in context.
A 2023 RMD Open study followed 2,878 postmenopausal Korean women with rheumatoid arthritis. At baseline, the early-menopause group had more previous fractures than the usual-menopause group, 24.5 percent versus 19.6 percent. It also had more neoplastic disease, 17.6 percent versus 7.9 percent. But this was a rheumatoid arthritis cohort, the study relied on self-reported menopause age, and newly developed fractures over 5 years were the same in both groups, 12.8 percent versus 12.8 percent. [9]
That evidence should not be used to tell a woman without rheumatoid arthritis that early menopause causes cancer or makes fracture inevitable. It is a reminder that autoimmune disease, steroid exposure, inflammation, cancer treatment history, and bone-risk factors can stack with menopause timing.
Brain evidence needs the same restraint. A 2023 JAMA Neurology cross-sectional study included 292 cognitively unimpaired adults, including 193 women. Earlier age at menopause and late hormone therapy initiation were associated with higher regional tau PET signal in the setting of elevated amyloid, but the exposures were self-reported and the design cannot prove causation or diagnose future dementia. [10]
For care decisions, this kind of imaging evidence supports a careful history and risk discussion. It does not turn hormone therapy into a dementia-prevention prescription.
Hormone therapy is a risk-reduction discussion, not a sales pitch
Premature ovarian insufficiency is different from deciding whether to start hormone therapy at the usual age of menopause.
American College of Obstetricians and Gynecologists says systemic hormone therapy is an effective approach to hypoestrogenism symptoms and long-term risk mitigation in primary ovarian insufficiency when no contraindications exist. The same guidance says hormone therapy is indicated to reduce osteoporosis, cardiovascular disease, and urogenital atrophy risk and to improve quality of life. Treatment generally continues until the average age of natural menopause, age 50 to 51. [1]
The 2022 North American Menopause Society position statement takes a similar timing-based view. It says women with primary ovarian insufficiency and premature or early menopause have higher risks of bone loss, heart disease, and cognitive or affective disorders associated with estrogen deficiency, and that hormone therapy can be used until at least the mean age of menopause when there is no contraindication. [4]
The 2024 international premature ovarian insufficiency guideline also recommends hormone therapy until the usual age of menopause for primary prevention, whether or not estrogen-deficiency symptoms are present. It adds two practical cautions: hormone therapy does not provide contraception, and a progestogen is needed with estrogen therapy when the uterus is intact. [2]
A 2022 systematic review and meta-analysis of hormone therapy in premature ovarian insufficiency included 30 reports from 28 studies and 4,004 participants. Hormone therapy was superior to non-treatment, placebo, calcitriol, or calcium for preserving bone mineral density, was associated with up to an 80 percent reduction in hot flush prevalence, and improved or stabilized quality-of-life measures. The authors noted that more data are needed for hard outcomes such as fractures and cardiovascular events. [7]
So the question is not "hormones or nothing." The safer question is: What is the diagnosis, what are the contraindications, what route and dose fit, is the uterus present, is contraception needed, what are the fertility goals, what is the bone-density status, and how will the plan be monitored?
What the review should cover
The next step is a clinician-led diagnosis and risk review, not only symptom tracking.
| Issue | Why it matters before 45 | What the visit should decide |
|---|---|---|
| Cause | Menopause timing can be natural, autoimmune, genetic, surgical, medication-related, cancer-treatment-related, or another diagnosis entirely. | Whether pregnancy, thyroid disease, prolactin disorder, medication effects, under-fueling, polycystic ovary syndrome, or premature ovarian insufficiency workup applies. |
| Bone health | Earlier estrogen loss can raise osteoporosis and fracture concern. | Whether bone-density testing, vitamin D and calcium review, strength training, fall-risk review, or bone medication discussion is needed. |
| Cardiovascular risk | Earlier menopause is linked with coronary and cardiometabolic risk signals. [5] [6] | Blood pressure, lipids, glucose, smoking, family history, weight trajectory, migraine, clot history, and exercise plan. |
| Fertility and contraception | Ovarian activity can be intermittent in premature ovarian insufficiency, and hormone therapy is not contraception. [1] [2] [3] | Whether contraception, fertility counseling, or reproductive endocrinology referral is needed. |
| Genitourinary symptoms | Vaginal dryness, urinary symptoms, and sexual pain can be part of low-estrogen exposure. | Whether systemic therapy, vaginal estrogen, moisturizers, lubricants, pelvic floor care, or infection evaluation applies. |
| Hormone therapy | Often discussed for risk reduction in premature ovarian insufficiency when no contraindication exists. [1] [2] [7] | Route, dose, uterus status, progestogen need, migraine, clot/stroke risk, cancer history, duration, and follow-up. |
This review may happen in primary care, gynecology, reproductive endocrinology, oncology survivorship, cardiology, bone-health care, or a combination. The right team depends on age, cause, symptoms, fertility goals, contraindications, and risk factors.
Red flags that should not wait
Do not treat these as routine hormone changes:
- Bleeding after 12 months without a period.
- Very heavy bleeding, bleeding between periods, or bleeding after sex.
- Pelvic pain, pregnancy possibility, galactorrhea, or thyroid symptoms.
- Symptoms before 40 that are being dismissed as routine perimenopause.
- Fracture after minimal trauma, major height loss, or new severe back pain.
- Chest pain, neurologic symptoms, fainting, severe shortness of breath, or a new severe headache.
- Sudden menstrual loss after chemotherapy, pelvic radiation, ovary removal, or another major medical treatment.
- Severe depression, anxiety, or distress about fertility.
Red flags do not mean medication is the default answer. They mean the first job is evaluation, not reassurance.
Who this fits, and who should avoid a shortcut
This review fits women with skipped or changing periods, hot flashes, night sweats, vaginal or urinary symptoms, sexual pain, mood or sleep changes, bone-risk concerns, or fertility questions before 45.
It is a poor fit to manage symptoms alone when the person is under 40, has sudden menstrual loss after medical treatment, has bleeding red flags, has a low-trauma fracture, has major cardiovascular or clot risk factors, has fertility goals, or has a cancer history that changes hormone therapy decisions.
A structured menopause assessment should decide which bucket the person is in: expected perimenopause after 45, early menopause from 40 through 44, premature ovarian insufficiency before 40, surgical or medical menopause, or another diagnosis.
What to ask your clinician
- Does my age and cycle pattern fit early menopause, premature ovarian insufficiency, medication effect, thyroid disease, prolactin disorder, pregnancy, or another cause?
- Which tests are useful at my age, and how should follicle-stimulating hormone be interpreted if I use hormonal contraception or no longer have a uterus?
- Do I need bone-density testing now, and what fracture-risk factors change that timing?
- What should we check for heart and metabolic risk: blood pressure, lipids, glucose, smoking, family history, migraine, clot history, or something else?
- If hormone therapy is discussed, what contraindications, route, dose, uterus status, progestogen need, and duration apply to me?
- Do I still need contraception or fertility counseling because ovarian activity can be intermittent?
- If I cannot use hormone therapy, what is the plan for bone, cardiovascular, genitourinary, mood, sleep, and symptom care?
- Who owns follow-up, and how often should the plan be revisited?
That last question matters. Early menopause care often spans years, so the plan should name what is being monitored, how often it is revisited, and who changes it if symptoms, risks, or goals shift.
Bottom line
Before 45, menopause symptoms should trigger a structured review.
The conversation should cover timing, cause, bone density, fracture risk, heart-risk factors, fertility or contraception goals, vaginal and urinary symptoms, mood, sleep, and whether hormone therapy is appropriate. The goal is not to sell hormones. It is to avoid treating earlier estrogen loss like ordinary timing.
Related reading:
- Bone Density After Menopause.
- Perimenopause at 35.
- What Is Perimenopause After 40?.
- Hormone Therapy After Menopause.
References
[1] Committee Opinion No. 698: Hormone Therapy in Primary Ovarian Insufficiency. Obstet Gynecol. 2017;129(5):e134-e141. doi:10.1097/aog.0000000000002044 https://pubmed.ncbi.nlm.nih.gov/28426619/
[2] Panay N, Anderson RA, Bennie A, et al. Evidence-based guideline: premature ovarian insufficiency(). Hum Reprod Open. 2024;2024(4):hoae065. doi:10.1093/hropen/hoae065 https://pubmed.ncbi.nlm.nih.gov/39660328/
[3] ACOG Committee Opinion No. 605. Primary Ovarian Insufficiency in Adolescents and Young Women. https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2014/07/primary-ovarian-insufficiency-in-adolescents-and-young-women
[4] “The 2022 Hormone Therapy Position Statement of The North American Menopause Society” Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767-794. doi:10.1097/gme.0000000000002028 https://pubmed.ncbi.nlm.nih.gov/35797481/
[5] Liu J, Jin X, Liu W, et al. The risk of long-term cardiometabolic disease in women with premature or early menopause: A systematic review and meta-analysis. Front Cardiovasc Med. 2023;10:1131251. doi:10.3389/fcvm.2023.1131251 https://pubmed.ncbi.nlm.nih.gov/37025693/
[6] Behboudi-Gandevani S, Arntzen EC, Normann B, Haugan T, Bidhendi-Yarandi R. Cardiovascular Events Among Women with Premature Ovarian Insufficiency: A Systematic Review and Meta-Analysis. Rev Cardiovasc Med. 2023;24(7):193. doi:10.31083/j.rcm2407193 https://pubmed.ncbi.nlm.nih.gov/39077000/
[7] Gonçalves CR, Vasconcellos AS, Rodrigues TR, Comin FV, Reis FM. Hormone therapy in women with premature ovarian insufficiency: a systematic review and meta-analysis. Reprod Biomed Online. 2022;44(6):1143-1157. doi:10.1016/j.rbmo.2022.02.006 https://pubmed.ncbi.nlm.nih.gov/35461762/
[8] Anagnostis P, Siolos P, Gkekas NK, et al. Association between age at menopause and fracture risk: a systematic review and meta-analysis. Endocrine. 2019;63(2):213-224. doi:10.1007/s12020-018-1746-6 https://pubmed.ncbi.nlm.nih.gov/30203119/
[9] Park EH, Kang EH, Lee YJ, Ha YJ. Impact of early age at menopause on disease outcomes in postmenopausal women with rheumatoid arthritis: a large observational cohort study of Korean patients with rheumatoid arthritis. RMD Open. 2023;9(1). doi:10.1136/rmdopen-2022-002722 https://pubmed.ncbi.nlm.nih.gov/36792311/
[10] Coughlan GT, Betthauser TJ, Boyle R, et al. Association of Age at Menopause and Hormone Therapy Use With Tau and β-Amyloid Positron Emission Tomography. JAMA Neurol. 2023;80(5):462-473. doi:10.1001/jamaneurol.2023.0455 https://pubmed.ncbi.nlm.nih.gov/37010830/